Evolent Health, Inc.EVHEarnings & Financial Report
Magellan Health Inc., is an American for-profit managed health care company and subsidiary of Centene that focuses on special populations and other specialty areas of healthcare. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. It ranked 390 on the Fortune 500 in 2021.
EVH Q3 2025 Key Financial Metrics
Revenue
$479.5M
Gross Profit
$99.8M
Operating Profit
$886.0K
Net Profit
$-20.9M
Gross Margin
20.8%
Operating Margin
0.2%
Net Margin
-4.4%
YoY Growth
-22.8%
EPS
$-0.24
Financial Flow
Evolent Health, Inc. Q3 2025 Financial Summary
Evolent Health, Inc. reported revenue of $479.5M for Q3 2025, with a net profit of $-20.9M (-4.4% margin). Cost of goods sold was $379.8M, operating expenses totaled $98.9M.
Key Financial Metrics
| Total Revenue | $479.5M |
|---|---|
| Net Profit | $-20.9M |
| Gross Margin | 20.8% |
| Operating Margin | 0.2% |
| Report Period | Q3 2025 |
Evolent Health, Inc. Annual Revenue by Year
Evolent Health, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.6B).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.6B |
| 2023 | $2.0B |
| 2022 | $1.4B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $556.1M | $639.7M | $647.1M | $621.4M | $646.5M | $483.6M | $444.3M | $479.5M |
| YoY Growth | 45.4% | 49.6% | 37.9% | 21.6% | 16.3% | -24.4% | -31.3% | -22.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.68B | $2.64B | $2.48B | $2.50B | $2.54B | $2.65B | $2.46B | $2.45B |
| Liabilities | $1.43B | $1.41B | $1.24B | $1.28B | $1.35B | $1.52B | $1.34B | $1.61B |
| Equity | $1.07B | $1.05B | $1.05B | $1.04B | $1.00B | $935.5M | $896.0M | $842.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $89.4M | $4.9M | $21.4M | $18.7M | $-26.2M | $4.6M | $-30.3M | $15.8M |